Placebo News and Research

RSS

Umeclidinium/vilanterol outperforms monotherapies in COPD

A combination of umeclidinium and vilanterol is more effective than each drug as monotherapy for the treatment of chronic obstructive pulmonary disease, research indicates.

13 Aug 2014

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease.

13 Aug 2014

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.

13 Aug 2014

Study: Effects of testosterone on brain's response to threat cues in healthy men

A new study in Biological Psychiatry reports on a neural circuit for male aggression. Testosterone, a steroid hormone, is well known to contribute to aggressive behavior in males, but the neural circuits through which testosterone exerts these effects have not been clear.

12 Aug 2014

Osteoporosis drugs may not protect women from breast cancer

Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF).

12 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Patient with mechanical heart pump receives new gene therapy for heart failure

For the first time in the world, a patient with a mechanical heart pump has received a new gene therapy for heart failure at Harefield Hospital, London.

11 Aug 2014

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma.

8 Aug 2014

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate has been approved since January 2014 for adults with relapsing remitting multiple sclerosis.

8 Aug 2014

BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences International, Inc. announced today that it has completed a pre-specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN).

6 Aug 2014

Whey protein drink can control erratic glucose levels associated with type 2 diabetes

Blood sugar surges - after-meal glucose "spikes" - can be life threatening for the 29 million Americans with diabetes. Diabetic blood sugar spikes have been linked to cardiovascular disease, cancer, Alzheimer's disease, kidney failure, and retinal damage.

5 Aug 2014

Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix.

1 Aug 2014

Researchers one step closer to finding treatment for dengue fever

There have been several news reports that the world's first dengue vaccine will be available next year. However, the latest clinical trials show that the vaccine only provides a protection of around 50 per cent for DENV-2 and DENV-1, which are commonly found in Singapore.

1 Aug 2014

Parenting skills of adults with ADHD improve when treated with medication

Parenting skills of adults with ADHD improve when their ADHD is treated with medication, according to Penn State College of Medicine researchers.

1 Aug 2014

Acupuncture helps cut fatigue, anxiety and depression in breast cancer patients using aromatase inhibitors

Use of electroacupuncture (EA) - a form of acupuncture where a small electric current is passed between pairs of acupuncture needles - produces significant improvements in fatigue, anxiety and depression in as little as eight weeks for early stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs) to treat breast cancer.

31 Jul 2014

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending.

31 Jul 2014

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone).

30 Jul 2014

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet.

29 Jul 2014

Placebo News and Research

Umeclidinium/vilanterol outperforms monotherapies in COPD

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Study: Effects of testosterone on brain's response to threat cues in healthy men

Osteoporosis drugs may not protect women from breast cancer

BioSpecifics Technologies total revenue for second quarter decreases by 19%

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Patient with mechanical heart pump receives new gene therapy for heart failure

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

Dimethyl fumarate offers no added benefits for adults with RRMS

BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

Whey protein drink can control erratic glucose levels associated with type 2 diabetes

Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

Researchers one step closer to finding treatment for dengue fever

Parenting skills of adults with ADHD improve when treated with medication

Acupuncture helps cut fatigue, anxiety and depression in breast cancer patients using aromatase inhibitors

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News